It is tempting to test if targeting CDC6 could overcome the adverse impact of p53 mutation in DLBCL, and if CDC6 inhibition could synergize with CHK1/2 inhibitor in DLBCL treatment. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.